Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Predictive Oncology Develops 3D Organoid Models Exclusively For Labcorp, Including Human And Rat Model

Author: Benzinga Newsdesk | June 12, 2025 07:57am

Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services.

As part of an ongoing agreement, Predictive Oncology recently developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, including a human and rat model. Both models represent the liver microenvironment and can be used for the evaluation of both drug metabolism and liver toxicity related to drugs.

Posted In: LH POAI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist